Provider of cardiology medical research and development services. The company has three on-going projects: neutrophil elastase inhibitors (NEI), bradykinin antagonists, and antigen-specific immunomodulation. NEIs have considerable potential in treating inflammatory conditions, e.g. adult respiratory distress syndrome (ARDS), ischemia reperfusion injury, arthritis, & inflammatory bowel disease. ARDS occurs with infections, trauma, & burns, and is 50-70% fatal. For ischemia, NEIs have shown efficacy is animal heart attack models. In 1990 the company's lead bradykinin antagonist, CP-0127, was discovered. CP-0127 has potential in affecting inflammatory conditions such as septic shock (gram positive & negative), traumatic shock, perioperative pain, asthma, burns, & migraines. The third project is an antigen-specific immunomodulation (ASIM) model. ASIM describes the molecular characteristics of an immune response to a specific antigen. ASIM provides a standardized approach to drug design for immune-related illnesses & allergies by suppressing the abnormal immune response to a specific antigen while leaving the rest of the immune system intact. The model is anticipated to receive broad patent protection for ASIM and provides the potential treatment for any disease which the antigen is the causative agent. Under development are compounds for systemic lupus erythematosus and ragweed allergy.